Review



recombinant mouse siglec e fc chimera  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems recombinant mouse siglec e fc chimera
    Recombinant Mouse Siglec E Fc Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pmc12167017-216-29-33?v=R%26D+Systems
    Average 93 stars, based on 6 article reviews
    recombinant mouse siglec e fc chimera - by Bioz Stars, 2026-07
    93/100 stars

    Images



    Similar Products

    93
    Sino Biological recombinant mouse siglec
    Recombinant Mouse Siglec, supplied by Sino Biological, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/10__1096_slash_fj__202500146rr-93-0-7?v=Sino+Biological
    Average 93 stars, based on 1 article reviews
    recombinant mouse siglec - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    TargetMol siglecg fc protein
    Siglecg Fc Protein, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pm40500109-138-0-5?v=TargetMol
    Average 93 stars, based on 1 article reviews
    siglecg fc protein - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant mouse siglec e fc chimera
    Recombinant Mouse Siglec E Fc Chimera, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pmc12167017-216-29-33?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    recombinant mouse siglec e fc chimera - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant mouse rm siglec g
    Recombinant Mouse Rm Siglec G, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pmc12187842-111-6-12?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    recombinant mouse rm siglec g - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant mouse siglec e fc
    Recombinant Mouse Siglec E Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pm39791710-105-26-31?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    recombinant mouse siglec e fc - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    TargetMol siglec g fc protein
    Siglec-G/10 promotes HNSCC transplant-tumor growth by reducing CD8+T cells infiltration. ( a ) Schematic <t>illustration</t> <t>of</t> <t>Siglec-G-Fc</t> and PD-1/PD-L1 inhibitory BMS-1 therapy. WT mice were subcutaneously inoculated with MTCQ1 HNSCC cells and administered with Siglec-G-Fc and BMS-1 or left untreated on days 3, 7, 10, 14 and 17. The tumor volume was monitored. ( b, c ) Volumes and weights of MTCQ1 subcutaneous tumorigenesis (n=5 mice per group), Scale bar: 1 cm. ( d, e ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and Siglec-G+ (red) are shown, and quantification analysis was performed in tumor tissues (n=5 fields of five mice per group), Scale bar: 100 µm. ( f ) The exhibition of subcutaneous tumorigenesis in Siglecg +/+ mice and Siglecg −/− mice. ( g ) The exhibition of isolated tumors. ( h, i ) Tumor growth curve and tumor weight of MTCQ1 cells derived subcutaneous tumorigenesis model in two groups for 31 days (n=5). ( j ) Flow cytometry analysis for percentage of Siglec-G+cells in CD45+and CD45- subsets in tumors; ( k ) Flow cytometry analysis for infiltration of macrophages, monocytes, neutrophils, dendritic cells, T cells, B cells and NK cells in tumors. ( l ) Flow cytometry analysis for percentage of CD8+T cells in tumors. ( m, n ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and F4/80+ (red) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 50 µm. ( o ) Representative images of multiplex immunofluorescence staining of F4/80+ (red), Siglec-G+ (green) and PD-L1+ (gold) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 100 µm. ns: not significant (p>0.05), *p<0.05, **p<0.01. Data are expressed as mean±SD. BMS-1: PD-1/PD-L1 inhibitor 1; DCs: dendritic cells; HNSCC: head and neck squamous cell carcinoma; i.p.: intraperitoneal; NK: natural killer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; Siglec: sialic acid binding immunoglobulin-like lectin; WT: wild type.
    Siglec G Fc Protein, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pmc12161403-153-0-3?v=TargetMol
    Average 93 stars, based on 1 article reviews
    siglec g fc protein - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    93
    R&D Systems siglec fc
    Siglec-G/10 promotes HNSCC transplant-tumor growth by reducing CD8+T cells infiltration. ( a ) Schematic <t>illustration</t> <t>of</t> <t>Siglec-G-Fc</t> and PD-1/PD-L1 inhibitory BMS-1 therapy. WT mice were subcutaneously inoculated with MTCQ1 HNSCC cells and administered with Siglec-G-Fc and BMS-1 or left untreated on days 3, 7, 10, 14 and 17. The tumor volume was monitored. ( b, c ) Volumes and weights of MTCQ1 subcutaneous tumorigenesis (n=5 mice per group), Scale bar: 1 cm. ( d, e ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and Siglec-G+ (red) are shown, and quantification analysis was performed in tumor tissues (n=5 fields of five mice per group), Scale bar: 100 µm. ( f ) The exhibition of subcutaneous tumorigenesis in Siglecg +/+ mice and Siglecg −/− mice. ( g ) The exhibition of isolated tumors. ( h, i ) Tumor growth curve and tumor weight of MTCQ1 cells derived subcutaneous tumorigenesis model in two groups for 31 days (n=5). ( j ) Flow cytometry analysis for percentage of Siglec-G+cells in CD45+and CD45- subsets in tumors; ( k ) Flow cytometry analysis for infiltration of macrophages, monocytes, neutrophils, dendritic cells, T cells, B cells and NK cells in tumors. ( l ) Flow cytometry analysis for percentage of CD8+T cells in tumors. ( m, n ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and F4/80+ (red) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 50 µm. ( o ) Representative images of multiplex immunofluorescence staining of F4/80+ (red), Siglec-G+ (green) and PD-L1+ (gold) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 100 µm. ns: not significant (p>0.05), *p<0.05, **p<0.01. Data are expressed as mean±SD. BMS-1: PD-1/PD-L1 inhibitor 1; DCs: dendritic cells; HNSCC: head and neck squamous cell carcinoma; i.p.: intraperitoneal; NK: natural killer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; Siglec: sialic acid binding immunoglobulin-like lectin; WT: wild type.
    Siglec Fc, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pmc12315822-134-5-8?v=R%26D+Systems
    Average 93 stars, based on 1 article reviews
    siglec fc - by Bioz Stars, 2026-07
    93/100 stars
      Buy from Supplier

    94
    MedChemExpress mouse siglec g
    Siglec-G/10 promotes HNSCC transplant-tumor growth by reducing CD8+T cells infiltration. ( a ) Schematic <t>illustration</t> <t>of</t> <t>Siglec-G-Fc</t> and PD-1/PD-L1 inhibitory BMS-1 therapy. WT mice were subcutaneously inoculated with MTCQ1 HNSCC cells and administered with Siglec-G-Fc and BMS-1 or left untreated on days 3, 7, 10, 14 and 17. The tumor volume was monitored. ( b, c ) Volumes and weights of MTCQ1 subcutaneous tumorigenesis (n=5 mice per group), Scale bar: 1 cm. ( d, e ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and Siglec-G+ (red) are shown, and quantification analysis was performed in tumor tissues (n=5 fields of five mice per group), Scale bar: 100 µm. ( f ) The exhibition of subcutaneous tumorigenesis in Siglecg +/+ mice and Siglecg −/− mice. ( g ) The exhibition of isolated tumors. ( h, i ) Tumor growth curve and tumor weight of MTCQ1 cells derived subcutaneous tumorigenesis model in two groups for 31 days (n=5). ( j ) Flow cytometry analysis for percentage of Siglec-G+cells in CD45+and CD45- subsets in tumors; ( k ) Flow cytometry analysis for infiltration of macrophages, monocytes, neutrophils, dendritic cells, T cells, B cells and NK cells in tumors. ( l ) Flow cytometry analysis for percentage of CD8+T cells in tumors. ( m, n ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and F4/80+ (red) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 50 µm. ( o ) Representative images of multiplex immunofluorescence staining of F4/80+ (red), Siglec-G+ (green) and PD-L1+ (gold) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 100 µm. ns: not significant (p>0.05), *p<0.05, **p<0.01. Data are expressed as mean±SD. BMS-1: PD-1/PD-L1 inhibitor 1; DCs: dendritic cells; HNSCC: head and neck squamous cell carcinoma; i.p.: intraperitoneal; NK: natural killer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; Siglec: sialic acid binding immunoglobulin-like lectin; WT: wild type.
    Mouse Siglec G, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+mouse+siglec/pm39111624-148-2-6?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    mouse siglec g - by Bioz Stars, 2026-07
    94/100 stars
      Buy from Supplier

    Image Search Results


    Siglec-G/10 promotes HNSCC transplant-tumor growth by reducing CD8+T cells infiltration. ( a ) Schematic illustration of Siglec-G-Fc and PD-1/PD-L1 inhibitory BMS-1 therapy. WT mice were subcutaneously inoculated with MTCQ1 HNSCC cells and administered with Siglec-G-Fc and BMS-1 or left untreated on days 3, 7, 10, 14 and 17. The tumor volume was monitored. ( b, c ) Volumes and weights of MTCQ1 subcutaneous tumorigenesis (n=5 mice per group), Scale bar: 1 cm. ( d, e ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and Siglec-G+ (red) are shown, and quantification analysis was performed in tumor tissues (n=5 fields of five mice per group), Scale bar: 100 µm. ( f ) The exhibition of subcutaneous tumorigenesis in Siglecg +/+ mice and Siglecg −/− mice. ( g ) The exhibition of isolated tumors. ( h, i ) Tumor growth curve and tumor weight of MTCQ1 cells derived subcutaneous tumorigenesis model in two groups for 31 days (n=5). ( j ) Flow cytometry analysis for percentage of Siglec-G+cells in CD45+and CD45- subsets in tumors; ( k ) Flow cytometry analysis for infiltration of macrophages, monocytes, neutrophils, dendritic cells, T cells, B cells and NK cells in tumors. ( l ) Flow cytometry analysis for percentage of CD8+T cells in tumors. ( m, n ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and F4/80+ (red) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 50 µm. ( o ) Representative images of multiplex immunofluorescence staining of F4/80+ (red), Siglec-G+ (green) and PD-L1+ (gold) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 100 µm. ns: not significant (p>0.05), *p<0.05, **p<0.01. Data are expressed as mean±SD. BMS-1: PD-1/PD-L1 inhibitor 1; DCs: dendritic cells; HNSCC: head and neck squamous cell carcinoma; i.p.: intraperitoneal; NK: natural killer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; Siglec: sialic acid binding immunoglobulin-like lectin; WT: wild type.

    Journal: Journal for Immunotherapy of Cancer

    Article Title: IL-4-STAT6-induced high Siglec-G/10 expression aggravates the severe immune suppressive tumor microenvironment and impedes the efficacy of immunotherapy in head and neck squamous cell carcinoma

    doi: 10.1136/jitc-2025-011474

    Figure Lengend Snippet: Siglec-G/10 promotes HNSCC transplant-tumor growth by reducing CD8+T cells infiltration. ( a ) Schematic illustration of Siglec-G-Fc and PD-1/PD-L1 inhibitory BMS-1 therapy. WT mice were subcutaneously inoculated with MTCQ1 HNSCC cells and administered with Siglec-G-Fc and BMS-1 or left untreated on days 3, 7, 10, 14 and 17. The tumor volume was monitored. ( b, c ) Volumes and weights of MTCQ1 subcutaneous tumorigenesis (n=5 mice per group), Scale bar: 1 cm. ( d, e ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and Siglec-G+ (red) are shown, and quantification analysis was performed in tumor tissues (n=5 fields of five mice per group), Scale bar: 100 µm. ( f ) The exhibition of subcutaneous tumorigenesis in Siglecg +/+ mice and Siglecg −/− mice. ( g ) The exhibition of isolated tumors. ( h, i ) Tumor growth curve and tumor weight of MTCQ1 cells derived subcutaneous tumorigenesis model in two groups for 31 days (n=5). ( j ) Flow cytometry analysis for percentage of Siglec-G+cells in CD45+and CD45- subsets in tumors; ( k ) Flow cytometry analysis for infiltration of macrophages, monocytes, neutrophils, dendritic cells, T cells, B cells and NK cells in tumors. ( l ) Flow cytometry analysis for percentage of CD8+T cells in tumors. ( m, n ) Representative images of multiplex immunofluorescence staining of CD8+ (green) and F4/80+ (red) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 50 µm. ( o ) Representative images of multiplex immunofluorescence staining of F4/80+ (red), Siglec-G+ (green) and PD-L1+ (gold) are shown, and quantification analysis was performed in tumor tissues (n=6 fields of six mice per group), Scale bar: 100 µm. ns: not significant (p>0.05), *p<0.05, **p<0.01. Data are expressed as mean±SD. BMS-1: PD-1/PD-L1 inhibitor 1; DCs: dendritic cells; HNSCC: head and neck squamous cell carcinoma; i.p.: intraperitoneal; NK: natural killer; PD-1: programmed cell death protein 1; PD-L1: programmed cell death ligand 1; Siglec: sialic acid binding immunoglobulin-like lectin; WT: wild type.

    Article Snippet: Siglec-G-Fc protein (#TMPJ-01201, TargetMol, USA) has an accession number of Q80ZE3 and its amino acid sequence extends from Met19 to Lys543.

    Techniques: Multiplex Assay, Immunofluorescence, Staining, Isolation, Derivative Assay, Flow Cytometry, Binding Assay